Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

ClearPoint Neuro, Inc.

$13.75 +1.18% NASDAQ: CLPT · 15-min delayed
  • SOLANA BEACH, California
  • Public · NASDAQ: CLPT
  • 172 employees
$386.6MMarket cap
$37.0MRevenue · FY2025
-$25.5MNet income
172Employees
CLPTNASDAQ
2012IPO

About ClearPoint Neuro, Inc.

ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$37.0M
Net income
-$25.5M
Total assets
$97.7M
Market cap
$386.6M
Gross margin
60.9%
Operating margin
-62.9%
Net margin
-60.3%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2024

Financial statements

Income statement

Revenue
$31.4M
Cost of revenue
$12.3M
Gross profit
$19.1M
Operating expenses
$38.9M
Operating income
-$19.7M
Income tax
$12.0K
Net income
-$18.9M
EPS (basic)
$-0.70
EPS (diluted)
$-0.70

Balance sheet

Total assets
$39.2M
Current assets
$33.4M
Total liabilities
$13.8M
Current liabilities
$10.4M
Shareholders’ equity
$25.4M

Cash flow

Operating cash flow
-$8.9M
Investing cash flow
-$275.0K
Financing cash flow
$6.2M
Net cash flow
-$3.0M

Statements via Polygon.io (SEC filings)

NASDAQ: CLPT
$13.75 +1.18%

15-minute delayed · data by Polygon.io

Past year

$8.66 $29.60

52-week range

Market cap
$386.6M
EPS (diluted)
$-0.7
Shares outstanding
28.1M
Open
Day range
Prev close
Volume
IPO date
May 18, 2012

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Reported a net loss of $25.5M in FY2025.
  • Revenue grew 145% from FY2020 to FY2024.
  • Gross margin of 60.9%, net margin -60.3%.
  • Trading 54% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review ClearPoint Neuro, Inc..

Write a review
Newsroom

News about ClearPoint Neuro, Inc.

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →